1250 mg of N-acetyl cysteine three times daily

1250 mg of N-acetyl cysteine three times daily
N-acetyl cysteine: 1250 mg of N- acetyl cysteine taken three times daily

N-acetyl Cysteine

placebo three times daily
Placebo: placebo taken three times daily

Placebo

Total

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Region of Enrollment

The MFIS is a self-report measure to rate fatigue in Multiple Sclerosis. The total score, ranging from 0 to 84 is the sum of three subscales (physical, cognitive, and psychosocial functioning). Higher numbers indicate greater fatigue. Modified fatigue Impact scale of more than 38 is one of the inclusion criteria for the study.

Modified Fatigue Impact Scale (MFIS) score at baseline

Number of adverse events reported since baseline visit that are related to N-acetyl cysteine will be compared to the number of adverse events reported by participants in the placebo group.

Number of Adverse Events Reported Since Baseline Visit That Are Related to N-acetyl Cysteine.

Change in fatigue score on questionnaires from baseline visit to week-4 is calculated for the Modified Fatigue Impact Scale (MFIS) questionnaire. The MFIS is a self-report measure to rate fatigue in Multiple Sclerosis. The total score, ranging from 0 to 84 is the sum of three subscales (physical, cognitive, and psychosocial functioning). Higher numbers indicate greater fatigue. Modified fatigue Impact scale of more than 38 is one of the inclusion criteria for the study. Study participants who scored higher value on the questionnaire at week-4 are considered to have worsened fatigue from the baseline visit.

Change in Fatigue Score on Questionnaires From Baseline

Baseline to week 4 change in blood GSH/GSSG ratio (wherein GSH is glutathione in reduced state and GSSG is glutathione in oxidized state) and grey matter GSH concentration on 7T MR spectroscopy (MRS) between groups. We hypothesize that fatigue is associated with the GSH/GSSG ratio.

Change in Level of Blood Markers From Baseline

Conventional T2/ T1-weighted images will be obtained at baseline for all subjects enrolled in the treatment phase of the study. We will perform brain MRI on 7T machine, and the sequences will be collected at baseline, and week-4 visit.

Changes in Metabolite Levels in Deep Grey Matter, and Surrounding White Matter on the Magnetic Resonance Images (MRI) From Baseline.

Overall Study

Emmanuelle Waubant, MD

Progressive Multiple Sclerosis

Fatigue

1250 mg of N- acetyl cysteine taken three times daily

N-acetyl cysteine

University of California San Francisco

A Study of Oxidative Pathways in MS Fatigue

A Phase 2 Randomized, Placebo- Controlled, Parallel Group, Double Blinded Single Center Study on Effect of N-acetyl Cysteine Compared to Placebo on Fatigue in Patients With Progressive Multiple Sclerosis

De-identified data will be made available for the primary and secondary outcome measures within six months of study completion.

University of California, San Francisco

Time of dosage comparison on blood serum melatonin phase and subjective sleepiness

To determine effects of 10mg daily melatonin on chemoreflex control, oxidation status, loop gain and apnea hypopnea index in obstructive sleep apnea

Obstructive Sleep Apnea

Melatonin

University of California, San Diego

The Effect of Melatonin on Sleep and Ventilatory Control in Obstructive Sleep Apnea

modified rebreathing tests will be utilised to assess the entire chemoreflex range

assess using standard sleep scoring criteria

assessed using flow from standard sleep study with method by Terrill (2014)

comparison of blood serum Angiotensin II, total glutathione, oxidized/reduced glutathione ratio, glutathione peroxidase, super oxide dismutase, C-Reactive protein, catalase pre and post treatment

assessed 2 hourly from 10pm to 6am to determine onset, peak and offset and phase resetting

To compare subjective daytime sleepiness following 1 week melatonin use versus baseline

To compare potential changes in sleep patterns and activity at home

Robert L. Owens

Assistant Professor of Medicine

National Institutes of Health (NIH)

National Heart, Lung, and Blood Institute (NHLBI)

50-150mg/kg of n-acetylcysteine intravenously once a week for at least two weeks.
600mg n-acetylcysteine orally twice daily except on day of infusion

Stage 0/1 Breast Cancer

Post Biopsy

Pre-surgery

IV/oral n-acetylcysteine

Sidney Kimmel Cancer Center at Thomas Jefferson University

Jefferson Myrna Brind Center for Integrative Medicine

Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer

To assess the feasibility of evaluating the effect of n-acetylcysteine on tumor cell metabolism by assessing the changes in expression of caveolin -1 and MCT4 in cancer associated fibroblasts in pre and post therapy breast tissue treated with NAC.

To confirm the safety of combined oral and IV NAC in patients with breast cancer. This will be evaluated by the number of participants with adeverse events and Grade 3/4 toxicities according to CTCAE v3.0

To access the changes in HIF-1 alpha and p65 subunit of NFB in tumor stroma in pre and post therapy breast tissue treated with NAC

To evaluate potential effects of NAC on quality of life and fatigue using the FACT-G, Brief Fatigue Inventory, and PROMIS quality assessment instruments.

Methadone and N-acetylcysteine for opioids abstaining

Opioids Use

Methadone; NAC

Methadone

Taichung Veterans General Hospital

Compare Methadone Combined With N-Acetyl-Cysteine (NAC) and Methadone Alone for Opioids Astaining

Evaluation Whether Higher Retention Rate is in Those of Combined Methadone With N-Acetyl-Cysteine Compared to Those With Methadone Alone During a Six-month Study

cysteine/väsymys

A Study of Oxidative Pathways in MS Fatigue

The Effect of Melatonin on Sleep and Ventilatory Control in Obstructive Sleep Apnea

Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer

Compare Methadone Combined With N-Acetyl-Cysteine (NAC) and Methadone Alone for Opioids Astaining

Täydellisin lääketieteellinen tietokanta tieteen tukemana